Nicola Ternette

Director, Immunopeptidomics at Enara Bio

Nicola joined Enara Bio in 2019 to lead the establishment of specialized immunopeptidomics facilities at the company and to guide research into Dark Antigen discovery.

Nicola concurrently holds an academic appointment at the University of Oxford where she heads the Antigen Discovery Group, specialising in sequencing the immunopeptidomes of multiple pathogen infection models, and analysis of the antigenic landscape of cancer and autoimmune diseases. This builds on Nicola’s postdoctoral research in Oxford where she utilized nanoflow ultra-performance liquid chromatography tandem mass spectrometry to identify viral antigens for the development of T-cell vaccines.

Nicola trained in Physics and Biochemistry at the Universities of Bonn, Greifswald and Bochum in Germany, and obtained her PhD evaluating DNA vaccines for Respiratory Syncytial Virus at the Institute for Molecular and Medical Virology in Bochum.


Org chart

No direct reports

Teams


Offices

This person is not in any offices


Enara Bio

Enara Bio’s mission is to shine a light on unconventional targets and develop the next generation of cancer immunotherapies designed to treat a broad patient population. Enara Bio is exploring the hidden depths of cancer and T-cell biology to discover and characterize novel immunotherapy targets, such as MR1-presented ligands and Dark Antigens™, which arise from altered cellular processes in cancer cells.


Industries

Employees

11-50

Links